LIXTE Biotechnology Holdings (NASDAQ: LIXT) has filed its Annual Report on Form 10-K for the year ended December 31, 2025, marking a period of significant transformation. The clinical-stage pharmaceutical and med-tech company reported progress across multiple fronts, including leadership changes, clinical advancements, and strategic acquisitions that are expected to shape its trajectory in cancer drug development.
Central to LIXTE's progress is the advancement of its lead compound, LB-100, a first-in-class clinical PP2A inhibitor. The company expanded clinical trials for LB-100 by adding new sites and increasing patient enrollment. These trials are evaluating LB-100 in combination with chemotherapies and immunotherapies for indications such as Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma. According to published preclinical data, LB-100 has the potential to enhance the efficacy of existing cancer treatments and improve patient outcomes, representing a novel approach in the field of activation lethality.
In a strategic move to broaden its technology platform, LIXTE completed the acquisition of Liora Technologies Europe Ltd. through its wholly owned subsidiary. Liora is developing electronically controlled proton therapy systems, including the proprietary LiGHT System, which the company believes offers significant advantages over current proton therapy technologies for treating tumors. This acquisition positions LIXTE at the intersection of pharmaceutical development and advanced medical devices.
To support its expanding operations, LIXTE raised more than $11 million during the year, strengthening its balance sheet and providing capital for continued clinical development and corporate initiatives. The company's filing also highlighted leadership changes that occurred in 2025, though specific details were not disclosed in the press release.
LIXTE's innovative approach is protected by a comprehensive patent portfolio, and the company is pioneering an entirely new field of cancer biology known as activation lethality. The company's focus remains on developing therapies that target cancer cell vulnerabilities, with LB-100 demonstrating tolerability at doses associated with anti-cancer activity in early trials.
The full 10-K filing and additional information about LIXTE's operations can be accessed through the InvestorBrandNetwork at ibn.fm/LP6QH. For more details on LIXTE's technology and pipeline, visit www.lixte.com. Forward-looking statements in the release are subject to risks and uncertainties, including those detailed in the company's SEC filings.
